{"id":"ins365-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Instillation site discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking IP3 receptor-mediated calcium release, INS365 decreases mucin secretion and inflammatory mediator release from conjunctival goblet cells and other ocular surface tissues. This mechanism addresses the underlying pathophysiology of dry eye disease by reducing both aqueous tear deficiency and mucin dysfunction.","oneSentence":"INS365 is a small-molecule selective inhibitor of inositol 1,4,5-trisphosphate (IP3) receptors that reduces intracellular calcium signaling in ocular surface cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:17.073Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"}]},"trialDetails":[{"nctId":"NCT07397949","phase":"PHASE4","title":"Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2026-03","conditions":"Dry Eye Disease (DED), Cataract","enrollment":60},{"nctId":"NCT07397936","phase":"PHASE4","title":"Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2024-08-01","conditions":"Dry Eye Disease (DED), Cataract","enrollment":55},{"nctId":"NCT06903884","phase":"PHASE3","title":"3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-12-30","conditions":"Vernal Keratoconjunctivitis","enrollment":94},{"nctId":"NCT07122635","phase":"","title":"Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery","status":"COMPLETED","sponsor":"Le Xuan Cung","startDate":"2024-10-03","conditions":"Dry Eye Disease","enrollment":60},{"nctId":"NCT07097922","phase":"NA","title":"Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients With Dry Eye After LASIK","status":"NOT_YET_RECRUITING","sponsor":"He Eye Hospital","startDate":"2025-08-01","conditions":"Dry Eye","enrollment":140},{"nctId":"NCT05682547","phase":"NA","title":"Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye","status":"COMPLETED","sponsor":"He Eye Hospital","startDate":"2022-12-01","conditions":"Diabetic Eye Problems","enrollment":99},{"nctId":"NCT06427031","phase":"PHASE3","title":"Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2023-07-14","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":271},{"nctId":"NCT06852105","phase":"NA","title":"Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK","status":"NOT_YET_RECRUITING","sponsor":"He Eye Hospital","startDate":"2025-02-28","conditions":"Dry Eye, Tear Break-Up Time","enrollment":76},{"nctId":"NCT06560580","phase":"NA","title":"Ditefossol Sodium 3% Eye Drops in Patients With Dry Eye","status":"COMPLETED","sponsor":"Tianjin Eye Hospital","startDate":"2021-11-15","conditions":"Dry Eye Disease","enrollment":97},{"nctId":"NCT06537349","phase":"NA","title":"Effects of 3% Diquafosol on Tear Film and Vision-related Quality of Life in Orthokeratology Lens Related Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"He Eye Hospital","startDate":"2024-08-15","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT05694026","phase":"NA","title":"Management of DE With IPL in Combination With DQS","status":"COMPLETED","sponsor":"He Eye Hospital","startDate":"2023-03-01","conditions":"Dry Eye","enrollment":360},{"nctId":"NCT05383612","phase":"NA","title":"To Evaluate the Efficacy of Diquafosol Sodium in the Treatment of MGD in Different Treatment Pattern","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2022-08-05","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":140},{"nctId":"NCT05720754","phase":"NA","title":"Temperature on Evaporative Dry Eye","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-04-02","conditions":"Dry Eye","enrollment":45},{"nctId":"NCT04980144","phase":"NA","title":"Diquafosol Ophthalmic Solution for Dry Eye Symptoms","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-03-03","conditions":"Diabetic Eye Problems","enrollment":101},{"nctId":"NCT05193331","phase":"NA","title":"Use of 3% Diquafosol Topical Ophthalmic Solution for Diabetic Dry Eye","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2023-04-01","conditions":"Diabetic Eye Problems","enrollment":70},{"nctId":"NCT05456061","phase":"NA","title":"Effect of ADDE on Tear Interferometry","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2018-08-01","conditions":"Tear, Dry Eye Syndromes","enrollment":152},{"nctId":"NCT04668118","phase":"PHASE4","title":"The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry Eye","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2021-02-01","conditions":"Dry Eye Syndromes, Computer Vision Syndrome, Asthenopia","enrollment":68},{"nctId":"NCT05346783","phase":"PHASE1, PHASE2","title":"Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients","status":"UNKNOWN","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2021-10-14","conditions":"Dry Eye Syndromes","enrollment":98},{"nctId":"NCT04548427","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of CKD-352","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-09-22","conditions":"Dry Eye Disease","enrollment":283},{"nctId":"NCT03640351","phase":"NA","title":"Clinical Effects of Diquas-S for Patients With Dry Eye After Cataract Surgery","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-08-15","conditions":"Dry Eye, Cataract Surgery","enrollment":150},{"nctId":"NCT02618304","phase":"NA","title":"Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2015-04-20","conditions":"Meibomian Gland Dysfunction","enrollment":45},{"nctId":"NCT00403715","phase":"PHASE3","title":"Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-02","conditions":"Dry Eye Disease","enrollment":500},{"nctId":"NCT00404131","phase":"PHASE3","title":"Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-03","conditions":"Dry Eye Disease","enrollment":500},{"nctId":"NCT02608489","phase":"NA","title":"Clinical Effects and Safety of 3% Diquafosol After Cataract Surgery","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2014-01","conditions":"Dry Eye Syndromes","enrollment":86},{"nctId":"NCT00403975","phase":"PHASE3","title":"Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Dry Eye Disease","enrollment":640},{"nctId":"NCT01381731","phase":"PHASE2","title":"A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Photorefractive Keratectomy","enrollment":14},{"nctId":"NCT00037661","phase":"PHASE3","title":"Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-04","conditions":"Keratoconjunctivitis Sicca","enrollment":222},{"nctId":"NCT00680108","phase":"PHASE2","title":"A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-09","conditions":"Dry Eye Disease","enrollment":62},{"nctId":"NCT00679718","phase":"PHASE2","title":"A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2000-01","conditions":"Dry Eye Disease","enrollment":150},{"nctId":"NCT00831662","phase":"PHASE3","title":"The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Dry Eye Disease","enrollment":490},{"nctId":"NCT00600288","phase":"PHASE3","title":"Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Dry Eye Disease","enrollment":261},{"nctId":"NCT01101984","phase":"NA","title":"Study of DE-089 Ophthalmic Solution in Patients With Dry Eye","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2010-02","conditions":"Dry Eye","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"INS365 Ophthalmic Solution","genericName":"INS365 Ophthalmic Solution","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"INS365 is a small-molecule selective inhibitor of inositol 1,4,5-trisphosphate (IP3) receptors that reduces intracellular calcium signaling in ocular surface cells. Used for Dry eye disease (keratoconjunctivitis sicca).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}